500288-84-6

Basic information

• Product Name: Benzonitrile, 4-[[4-[(3,3',5-trimethyl[1,1'-biphenyl]-4-yl)amino]-2-pyrimidinyl]amino]-
• CAS NO: 500288-84-6
• Molecular Formula: C26H23N5
• Molecular Weight: 405.502
• Mol File: 500288-84-6.mol

Chemical Properties

• CAS DataBase Reference: Benzonitrile, 4-[[4-[(3,3',5-trimethyl[1,1'-biphenyl]-4-yl)amino]-2-pyrimidinyl]amino]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzonitrile, 4-[[4-[(3,3',5-trimethyl[1,1'-biphenyl]-4-yl)amino]-2-pyrimidinyl]amino]-(500288-84-6)
• EPA Substance Registry System: Benzonitrile, 4-[[4-[(3,3',5-trimethyl[1,1'-biphenyl]-4-yl)amino]-2-pyrimidinyl]amino]-(500288-84-6)

Safety Data

• Hazardous Substances Data: 500288-84-6(Hazardous Substances Data)

Upstream product

• 873-74-5 4-Aminobenzonitrile 
• 244768-32-9 4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile 
• 17933-03-8 m-tolylboronic acid 
• 374067-85-3 4-((4-((4-bromo-2,6-dimethylphenyl)amino)pyrimidin-2-yl)amino)benzonitrile 

Relevant articles and documents

Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1

A novel series of diarylpyrimidine (DAPY) derivatives bearing the biphenyl motif with multiple substituted groups was synthesized as human immunodeficiency virus (HIV)-1 non-nucleoside reverse transcriptase inhibitors. All of the target compounds were evaluated for their in vitro activity against HIV in MT-4 cells. Most of the compounds exhibited excellent activity with low nanomolar EC50 values against wild-type, single and double mutant HIV-1 strains. Compound 4b displayed an EC50 value of 1 nM against HIV-1 IIIB, 1.3 nM against L100I, 0.84 nM against K103 N, 1.5 nM against Y181C, 11 nM against Y188L, 2 nM against E138K, 10 nM against K103 N + Y181C, and almost 110 nM against F227L + V106. The improvement in the selectivity and potency of the target molecules against the wild-type and mutant HIV-1 strains validated our hypothesis. The biphenyl ring in the DAPY derivatives could strengthen the π-π stacking effect between the target molecule and the non-nucleoside inhibitor-binding pocket in the reverse transcriptase by extending the conjugating systems. This research represented a significant step toward the discovery of novel therapeutic DAPYs for treating acquired immunodeficiency syndrome in patients infected with HIV-1.

Pharmaceutical compositions comprising a basic drug compound, a surfactant, and a physiologically tolerable water soluble acid

The invention provides a novel pharmaceutical composition comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base characterized in that the acid respectively base:drug compound ratio is at least 1:1 by weight.